Saturday, August 23, 2014 9:22:13 AM
new initiative to generate investment into the company will allow us to recommence these trials and move towards
selling the equine product on the open market. As a result, the Company is still in development and approval stage.
We are looking to raise the estimated $2 million required to obtain US Food and Drug Administration approval of the
patented process for humans and to make the product available to our targeted markets. This process has continued
and has found some success following the release into the market of converted stocks. Interest in our shares has
been encouraging with the conversion of a large portion of our long-term debt into Common Stock which has in turn
necessitated our increasing the authorized capital of the Company. Although we are still short of our targetted
investment level which would allow trials to recommence, we will be looking to take advantage of the market activity
by issuing new shares in the near future as well as developing other long-term investment possibilities."
PLEASE NOTE THAT IT TAKES YEARS TO GET FDA APPROVAL AND TAKES YEARS OF CLINICAL TESTING AND POSSIBLY $100'S OF MILLIONS OF DOLLARS.
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143534.htm
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM